Latest Healthcare News

Proteomics International has expanded its partnership with the University of Melbourne and Royal Women’s Hospital to further validate and develop its PromarkerEndo blood test, aiming to revolutionize endometriosis diagnosis.

Bank of Queensland reported a robust FY25 with 12% growth in cash earnings and significant progress in its digital banking and branch conversion initiatives. The bank’s focus on productivity and specialist business lending underpins its optimistic outlook despite ongoing economic uncertainties.

Argenica Therapeutics reports encouraging functional improvements in stroke patients treated with ARG-007, setting the stage for a targeted Phase 2b trial focused on patient-centered outcomes.

Telix Pharmaceuticals reports a robust 53% revenue jump in Q3 2025 and raises its full-year guidance, underpinned by key reimbursement wins and expanding clinical programs.

333D Ltd reports a fifth consecutive quarter of revenue growth, secures $1 million in fresh capital, and expands its blockchain healthcare initiatives while building a strategic Bitcoin treasury.

Clarity Pharmaceuticals’ Co-PSMA Phase II trial shows its Cu-SAR-bisPSMA diagnostic agent detects more prostate cancer lesions than current standard imaging, promising earlier and more accurate recurrence detection.

Tryptamine Therapeutics has enrolled the first patient in its pioneering clinical trial testing TRP-8803, an IV-infused psilocin formulation, for Binge Eating Disorder. The study aims to evaluate safety and efficacy, potentially reshaping treatment options for millions.

EMVision Medical Devices has received a $3 million government grant to fund a clinical study demonstrating its emu™ brain scanner's impact on accelerating stroke diagnosis in rural emergency departments.

ReNerve Limited has achieved its first commercial sales of the EmpliQ™ amniotic tissue products, marking a significant step in its transition from R&D to commercialisation. The EmpliQ™ range complements its existing nerve repair solutions and targets a growing global wound care market.

Enero Group reports a robust 13% increase in EBITDA for FY26 Q1, powered by strong Australian agency performance and strategic cost cuts, while Hotwire Global undergoes leadership changes and cost optimisation.

Pacific Edge reports a 9% decline in Cxbladder test volumes amid Medicare coverage loss but gains momentum with new clinical validation and a CMS pricing boost.

Resonance Health reveals a robust growth strategy targeting $17 million revenue by FY26, powered by AI-enhanced medical imaging and global clinical trial services expansion.